2025-11-06T12:12:30-06:00 2024-12-31 872525370 CITRIN COOPERMAN ADVISORS LLC 180 PARK AVENUE SUITE 200 FLORHAM PARK NJ 07932 990 2024-01-01 510181215 ISRAEL CANCER RESEARCH FUND INC ISRA 2129699800 52 VANDERBILT AVENUE 1410 NEW YORK NY 10017 RICHARD EDELHEIT TREASURER 2129699800 2025-11-03 1 1 AMANDA ADAMS P00748038 9732180500 2025-11-03 2024 2025-03-06 01:10:19Z RICHARD EDELHEIT 52 VANDERBILT AVENUE 1410 NEW YORK NY 10017 19918132 0 X WWW.ICRFONLINE.ORG X 1975 NY TO SUPPORT CANCER RESEARCH IN ISRAEL, FOR THE BENEFIT OF ISRAEL AND ALL MANKIND. 38 38 13 45 0 0 7783907 7669629 0 0 203373 1553355 -259109 -158410 7728171 9064574 3461666 3657154 0 0 2088197 1864230 0 0 1224319 803432 776690 6353295 6298074 1374876 2766500 19252119 20966521 3284864 2420122 15967255 18546399 X TO SUPPORT CANCER RESEARCH IN ISRAEL, FOR THE BENEFIT OF ISRAEL AND ALL MANKIND. 0 0 3027012 2527154 PROVIDED CANCER RESEARCH FUNDING FOR ISRAELI SCIENTISTS. ICRF IS THE LARGEST NON-PROFIT IN NORTH AMERICA DEDICATED TO SUPPORTING CANCER RESEARCH IN ISRAEL. OVER THE LAST NEARLY 50 YEARS, ICRF HAS PROVIDED MORE THAN $98 MILLION TO SUPPORT CANCER RESEARCH IN ISRAEL, FUNDING NEARLY 3,000 RESEARCH PROJECTS. IN 2024, WE AWARDED 58 RESEARCH GRANTS VALUED AT NEARLY $3.6M. TYPICALLY, 60-80 GRANTS ARE FUNDED ANNUALLY, BASED ON AN EVALUATION AND PRIORITIZATION BY INDEPENDENT REVIEW PANELS CONSISTING OF 40-50 LEADING CANCER SCIENTISTS FROM NORTH AMERICAN BIOMEDICAL RESEARCH CENTERS. ICRF GRANT CATEGORIES ARE TAILORED TO SUPPORT CANCER RESEARCHERS AT ALL OF THE VARIOUS STAGES OF THEIR CAREERS, AND WE ARE PROUD TO HAVE HELPED SUPPORT MANY OF TODAY'S MOST OUTSTANDING SCIENTISTS AT THE EARLIEST STAGES IN THEIR CAREERS. ICRF SEEKS TO CAPITALIZE ON THE SIGNIFICANTLY LOWER COSTS OF CONDUCTING CANCER RESEARCH IN ISRAEL. ALL AWARDS GO DIRECTLY TO THE DESIGNATED RESEARCHER WITHOUT ANY REDUCTION FOR OVERHEAD. 879006 725000 SUPPORTED THE DEVELOPMENT OF THE NEXT GENERATION OF ISRAELI CANCER SCIENTISTS. ICRF IS COMMITTED TO FACILITATING THE DEVELOPMENT OF FUTURE CANCER SCIENTISTS IN ISRAEL. TOWARDS THIS END ICRF FUNDS THREE TYPES OF GRANTS: POSTDOCTORAL FELLOWSHIP AWARDS, RESEARCH CAREER DEVELOPMENT AWARDS, AND CLINICAL RESEARCH CAREER DEVELOPMENT AWARDS. FELLOWSHIPS SUPPORT MDS AND PHDS WHO HAVE JUST COMPLETED THEIR POSTGRADUATE TRAINING. THESE AWARDS CAN BE USED TO SUPPORT SALARIES OR RESEARCH COSTS, WHILE THESE INDIVIDUALS APPRENTICE IN THE LABORATORIES OF SENIOR INVESTIGATORS. CAREER DEVELOPMENT AWARDS ARE TO ENHANCE THE RESEARCH CAPABILITIES OF YOUNG ISRAELI SCIENTISTS IN THE FORMATIVE PHASE OF THEIR CAREERS. CANDIDATES MUST HAVE DEMONSTRATED OUTSTANDING POTENTIAL FOR CONTRIBUTIONS TO CANCER RESEARCH AND MUST EXHIBIT GREAT POTENTIAL TO BECOME INDEPENDENT INVESTIGATORS RESEARCH. SUPPORTING THESE NEWLY LAUNCHED SCIENTISTS, ENHANCES THEIR OPPORTUNITIES IN ISRAEL AND ALLOWS THEM TO OPTIMIZE THEIR WORK WITHOUT EMIGRATING TO OTHER ADVANCED COUNTRIES. 491031 405000 SUPPORTED COLLABORATIVE CANCER RESEARCH CONDUCTED BY ISRAELI SCIENTISTS IN ASSOCIATION WITH NORTH AMERICAN CANCER SCIENTISTS. CANCER SCIENCE OFTENTIMES REQUIRES MULTI-DISCIPLINARY APPROACHES, ENGAGEMENT WITH HIGHLY SPECIALIZED AREAS OF SCIENCE, AND EXPENSIVE EQUIPMENT THAT IS NOT EASILY ACCESSED. COLLABORATIONS BETWEEN SCIENTISTS IN ISRAEL AND NORTH AMERICA CAN ADDRESS THESE CHALLENGES, FOSTER UNEXPECTED SYNERGIES, AND ENHANCE BOTH INTELLECTUAL CURIOSITY AND INNOVATION. ICRF PROMOTES COLLABORATION BY SUPPORTING GRANTS THAT FUND PROMISING CANCER RESEARCH PROJECTS BEING CONDUCTED ON A COLLABORATIVE BASIS BETWEEN INVESTIGATORS IN ISRAEL AND AN AMERICAN OR CANADIAN RESEARCH INSTITUTION. 4397049 1 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 25 0 1 13 1 0 0 0 0 0 0 0 0 0 0 0 0 X 38 38 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 0 0 NY CA CT FL IL MD MA NJ OR PA VA CO GA KS ME MI NH NC DC OH RI TN SC WA X X TANIA ORENSTEIN 2129699800 52 VANDERBILT AVENUE 1410 NEW YORK NY 10017 DAVID ABRAMSON PRESIDENT 2.00 X X 0 0 0 BRYNA GOLDBERG CHAIR 2.00 X X 0 0 0 ARNOLD M BASKIES MD VICE PRESIDENT 2.00 X X 0 0 0 NANCY MAIZELS PHD VICE PRESIDENT 2.00 X X 0 0 0 RICHARD EDELHEIT TREASURER 2.00 X X 0 0 0 CYNTHIA PERL SECRETARY 2.00 X X 0 0 0 BONNIE E FISH EXECUTIVE COMMITTEE MEMBER 2.00 X 0 0 0 LESLIE R FREEDMAN PHD EXECUTIVE COMMITTEE MEMBER 2.00 X 0 0 0 LISA OVED EXECUTIVE COMMITTEE MEMBER 2.00 X 0 0 0 CHARLES SERLIN EXECUTIVE COMMITTEE MEMBER 2.00 X 0 0 0 ROBERT BARD TRUSTEE 2.00 X 0 0 0 BRUCE BARRON TRUSTEE 2.00 X 0 0 0 CHARLES BEN DAYAN TRUSTEE 2.00 X 0 0 0 JEFFREY BERNSTEIN TRUSTEE 2.00 X 0 0 0 JEFFREY BLY TRUSTEE 2.00 X 0 0 0 VERA FINKELSTEIN TRUSTEE 2.00 X 0 0 0 PAUL T FOX TRUSTEE 2.00 X 0 0 0 TAMIR GILAT TRUSTEE 2.00 X 0 0 0 BRAD GOLDHAR TRUSTEE 2.00 X 0 0 0 KENNETH E GOODMAN TRUSTEE 2.00 X 0 0 0 ROBERT GREENE TRUSTEE 2.00 X 0 0 0 MARYANNE GREENFIELD TRUSTEE 2.00 X 0 0 0 SAMUEL HERZFELD TRUSTEE 2.00 X 0 0 0 ALISON HIMEL TRUSTEE 2.00 X 0 0 0 MARK A ISRAEL MD TRUSTEE 2.00 X 0 0 0 BARBARA KASELL TRUSTEE 2.00 X 0 0 0 SUSAN MATTESON KING TRUSTEE 2.00 X 0 0 0 RICHARD LIPKIN TRUSTEE 2.00 X 0 0 0 DAVID MALKIN MD TRUSTEE 2.00 X 0 0 0 LEN MARK TRUSTEE 2.00 X 0 0 0 PATRICK MUNDT TRUSTEE 2.00 X 0 0 0 LISA OVED TRUSTEE 2.00 X 0 0 0 JOEL PELOFSKY TRUSTEE 2.00 X 0 0 0 JERRY SILBER TRUSTEE 2.00 X 0 0 0 GERELD SOFF MD TRUSTEE 2.00 X 0 0 0 MATTHEW WEITZMAN PHD TRUSTEE 2.00 X 0 0 0 JULIA WEKSLER TRUSTEE 2.00 X 0 0 0 SIDNEY J WINAWER MD TRUSTEE 2.00 X 0 0 0 ALAN HERMAN EXECUTIVE DIRECTOR 40.00 X 246274 0 79703 BERYL CHERNOV FORMER NATIONAL EXECUTIVE DIR.(1/24) 40.00 X 98640 0 22409 TANIA ORENSTEIN CONTROLLER 40.00 X 176015 0 13410 ALLYSON GREENFIELD CHICAGO EXECUTIVE DIRECTOR 40.00 X 155587 0 38383 DAVID KWESKIN CONNECTICUT DIRECTOR 40.00 X 117987 0 8677 794503 0 162582 4 0 1 0 0 1888965 5780664 105899 7669629 502721 502721 11376808 10326174 1050634 1050634 1050634 368974 1888965 527384 -158410 -158410 9064574 0 0 1394945 3657154 3657154 830422 253498 243800 333124 812024 269362 92211 450451 14759 4549 1553 8657 90712 44923 8952 36837 116313 36767 22233 57313 23392 14642 8750 66890 44678 22212 244395 259 130735 113401 44608 216 10538 33854 40722 8098 14471 18153 72576 23011 21157 28408 82951 41319 41632 33727 14860 6572 12295 99906 17820 2970 79116 5353 5353 62170 25213 15209 21748 6298074 4397049 676706 1224319 3057836 2041789 2542221 343282 2204696 1712327 64769 94077 447417 323609 185978 123808 10240998 15542928 400000 675000 555621 433310 19252119 20966521 127141 79310 2422500 1775000 15288 735223 550524 3284864 2420122 X 7515370 11827409 8451885 6718990 15967255 18546399 19252119 20966521 2766500 -187356 0 X 0 1 X 1 0 X 4541503 6704934 5860881 7783907 7669629 32560854 4541503 6704934 5860881 7783907 7669629 32560854 3959413 28601441 161186 202683 182826 198980 502721 1248396 33809250 9050 0.84600 0.81480 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER - RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 3917076 523321 60000 4380397 3405989 511087 3917076 3753296 -347307 3405989 3311782 441514 3753296 3032805 278977 3311782 0.43104 0.56897 0 0 310377 200045 110332 11943 11943 0 125097 111621 13476 123808 OPERATING LEASE LIABILITIES 433610 FINANCE LEASE LIABILITY 116914 550524 X 9378704 -187356 326399 139043 9239661 -175087 -175087 9064574 6799560 326399 175087 501486 6298074 0 6298074 PART V, LINE 4: THE ORGANIZATION'S ENDOWMENT FUNDS ARE INTENDED TO SUPPORT CANCER RESEARCH IN ISRAEL, SUBJECT TO DONOR RESTRICTIONS. THE PERCENTAGE REPORTED FOR PERMANENT ENDOWMENTS INCLUDES AMOUNTS THAT MUST BE MAINTAINED IN PERPETUITY AS WELL AS ACCUMULATED EARNINGS ON SUCH AMOUNTS THAT HAVE NOT YET BEEN APPROPRIATED FOR EXPENDITURE. PART X, LINE 2: THE ORGANIZATION RECOGNIZES AND MEASURES ITS UNRECOGNIZED TAX BENEFITS IN ACCORDANCE WITH FASB ASC 740, INCOME TAXES. UNDER THIS GUIDANCE, THE ORGANIZATION ASSESSES THE LIKELIHOOD, BASED ON THEIR TECHNICAL MERIT, THAT TAX POSITIONS WILL BE SUSTAINED UPON EXAMINATION BASED ON THE FACTS, CIRCUMSTANCES, AND INFORMATION AVAILABLE AT THE END OF EACH PERIOD. THE MEASUREMENT OF UNRECOGNIZED TAX BENEFITS IS ADJUSTED WHEN NEW INFORMATION IS AVAILABLE OR WHEN AN EVENT OCCURS THAT REQUIRES A CHANGE. MANAGEMENT HAS EVALUATED THE ORGANIZATION'S TAX POSITIONS AND HAS CONCLUDED THAT THE ORGANIZATION HAS TAKEN NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS. PART XI, LINE 4B - OTHER ADJUSTMENTS: DIRECT FUNDRAISING EVENT EXPENSES -175,087. PART XII, LINE 2D - OTHER ADJUSTMENTS: DIRECT FUNDRAISING EVENT EXPENSES 175,087. 1 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 3657154 MIDDLE EAST AND NORTH AFRICA 0 0 INVESTMENTS 675000 0 0 0 0 0 0 4332154 0 4332154 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 265000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 220000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 315000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 83333 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 823333 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 107155 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 165000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 455000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 615000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 608333 WIRE 0 10 0 1 0 1 0 0 0 PART I, LINE 2: SCIENTISTS ARE REQUIRED TO PROVIDE REPORTS THAT SHOW THAT THEY COMPLIED WITH THE TERMS OF THE GRANTS FOR CANCER RESEARCH. PART I, LINE 3: THE AMOUNT REPORTED IN PART I FOR GRANT EXPENDITURES WAS DETERMINED USING THE ACCRUAL METHOD OF ACCOUNTING. THE AMOUNT REPORTED IN PART I FOR INVESTMENTS REPRESENTS THE ORGANIZATION'S COST BASIS OF SUCH INVESTMENTS AS OF THE END OF THE TAX YEAR. IL GALA 800148 728148 72000 16368 97570 78121 NY TOWER OF HOPE GALA 367808 331808 36000 23425 31718 1000 25214 10 1089983 829009 260974 24034 77945 43923 108066 2257939 1888965 368974 24034 117738 173211 1000 211401 527384 -158410 X X X 1 0 0 0 0 0 0 1 0 ALAN HERMAN EXECUTIVE DIRECTOR 246274 0 0 0 0 0 5683 0 74020 0 325977 0 0 0 ALLYSON GREENFIELD CHICAGO EXECUTIVE DIRECTOR 155587 0 0 0 0 0 3790 0 34593 0 193970 0 0 0 TANIA ORENSTEIN CONTROLLER 174015 0 2000 0 0 0 3675 0 9735 0 189425 0 0 0 PART I, LINE 4A BERYL CHERNOV RECEIVED SEVERANCE OF $93,730 EQUAL TO 3 MONTHS OF PAY. PART I, LINE 7 DISCRETIONARY MERIT-BASED YEAR-END BONUSES WERE AWARDED DURING THE YEAR. X 10 51784 SALES PROCEEDS X 5 1144 COST X SPORTS TICKETS AND/OR PRIVILEGES 76 46221 FMV X PROMOTIONAL ITEMS 1 6750 FMV 0 0 1 0 PART I, COLUMN (B): THE AMOUNT REPORTED IN COLUMN B IS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY THE TREASURER AND CONTROLLER AND DISTRIBUTED TO THE BOARD PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C MEMBERS OF THE BOARD, AS WELL AS ALL OFFICERS AND ALL EMPLOYEES, ARE REQUIRED TO SIGN WRITTEN CONFLICT OF INTEREST STATEMENTS ON AN ANNUAL BASIS. ANY CONFLICTS ARE DISCLOSED IN WRITING TO THE CHAIRPERSON OF THE BOARD AND APPROPRIATE ACTION IS TAKEN TO RESOLVE ANY CONFLICTS, INCLUDING REQUESTING THAT INTERESTED PERSON TO RECUSE THEMSELVES FROM VOTING AND PARTICIPATING IN THE BOARD DISCUSSIONS OF SUCH INTERESTS. A COPY OF EACH DISCLOSURE STATEMENT SHALL BE AVAILABLE TO ANY TRUSTEE OF THE ORGANIZATION UPON REQUEST. FORM 990, PART VI, SECTION B, LINE 15A EXECUTIVE COMMITTEE MEMBERS ARE INVOLVED IN THE DECISION MAKING PROCESS ON THE COMPENSATION OF THE EXECUTIVE DIRECTOR. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S AUDITED FINANCIAL STATEMENTS ARE AVAILABLE TO THE GENERAL PUBLIC ON THE ORGANIZATION WEBSITE AND UPON REQUEST. THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE MADE AVAILABLE UPON REQUEST.